Uveitis Treatment Market Share

Uveitis Treatment Market Overview

The Uveitis Treatment Market is expected to reach USD 1.03 Billion by 2032 at CAGR 5.6% during the forecast period 2023-2032. Uveitis is a form of inflammation that occurs in the middle layer of the eyeball known as the uvea. It is accompanied by symptoms such as pain, redness of the eyes, and blurred vision. It mainly occurs in people aged between 20 to 50 years. There are three main types of uveitis anterior uveitis, posterior uveitis, and intermediate uveitis.

For instance, in June 2016, AbbVie Inc received FDA (Food and Drug Administration) approvals for its HUMIRA in the treatment of non-infectious intermediate, posterior, and panuveitis. This helped it to strengthen its uveitis treatment product portfolio.

A key factor propelling the uveitis treatment market is the worldwide increase in uveitis incidence and prevalence. The increased incidence of uveitis can be attributed to a number of factors, including autoimmune illnesses, infections, and inflammatory disorders. Moreover, the therapy of uveitis has also been progressed thanks to the discovery of new drugs such biologic treatments, immunosuppressants, and targeted medicines. 

The development of more precise and efficient methods of treatment is a major factor driving the market forward. Therefore, the early diagnosis and quick treatment of uveitis have resulted from rising awareness about the condition among healthcare professionals and patients. As a result, there is a greater need for effective treatments for uveitis.

Rapid market expansion may be attributed, in part, to the increase in spending on research projects in the ophthalmology sector. Refractory posterior or intermediate uveitis are the subject of a growing number of clinical trials across the world. Several randomized, controlled trials of alternative treatments to the conventional corticosteroid therapy for noninfectious uveitis, such as mycophenolate mofetil and methotrexate, are currently enrolling patients.

Moreover, the improvement of therapy choices for ocular inflammatory problems is largely attributable to the creation of biological therapies through intensive R&D efforts. As a result, this is increasing the need for these medications and stimulating the market.

Market Influencer

Rising prevalence of uveitis, increasing R&D expenditure, and product launches are likely to impact the growth of the uveitis treatment market positively.

Market Drivers

• Increased R&D expenditure in the healthcare industry will support the growth of the uveitis treatment market.


• The growth of the market is driven by the increasing number of product launches in the uveitis treatment market. For example, in October 2018, EyePoint Pharmaceuticals received FDA approval for Yutiq (fluocinolone acetonide intravitreal implant). This product is used in the treatment of chronic non-infectious uveitis.


• Increasing prevalence of the uveitis across the globe

Market Restraints

• Side-effect related to corticosteroid drugs is likely to hamper the growth of the uveitis treatment market during the forecast period

Uveitis Treatment Market Segmentation

By Type

• Anterior Uveitis: In anterior uveitis, inflammation forms in the middle layer of the eye that includes the iris and adjacent tissue. This segment holds the most significant share in the type segment. Mainly topical drops such as corticosteroid drops are prescribed by the physician in the treatment of the anterior uveitis.


• Intermediate Uveitis: It occurs in children as well as young adults. It accounts for 2% 31% of all uveitis patients and incidence of the intermediate uveitis between 1.4% to 2% in Germany.


• Posterior Uveitis: In posterior uveitis, the inflammation primarily forms in the retina and choroid area of the eye.


• Others

• Corticosteroids Drugs: This drug class is most commonly used for the treatment of uveitis. It expected to hold the largest share in the uveitis treatment market due to the increasing preference of this drug class and desirable outcomes. Major corticosteroid brands in the uveitis treatment market are Ozurdex (Allergan PLC) and Triesence suspension (Novartis AG).


• Anti-Inflammatory Drugs: In chronic uveitis, non-steroid anti-inflammatory drugs are used to treat inflammation over a more extended period.


• Immunosuppressive Drugs: Maximum immunosuppressive agents have significant adverse effects due to which these drugs are not used very often for the treatment of the uveitis.

• Hospitals: The largest segment, hospitals are usually the primary points for diagnosis, treatment, and rehabilitation of individuals. In 2018, the hospital's segment held the largest share of the uveitis treatment market.


• Specialty Clinics: Consisting of long-term care for chronic patients and the elderly, this is a fast-growing market segment, especially in developed nations.


• Others